Advance in human papillomavirus major capsid protein L1-based vaccines
10.3760/cma.j.issn.0254-5101.2019.010.011
- VernacularTitle:基于人乳头瘤病毒主要衣壳蛋白L1的疫苗研究进展
- Author:
Chunting HUA
1
;
Siyuan SUN
;
Hao CHENG
;
Rui HAN
Author Information
1. 浙江大学医学院附属邵逸夫医院皮肤科
- Keywords:
Human papillomavirus;
Major capsid protein L1;
Virus like particle;
HPV vaccine
- From:Chinese Journal of Microbiology and Immunology
2019;39(10):788-793
- CountryChina
- Language:Chinese
-
Abstract:
L1 is the major capsid protein of human papillomavirus (HPV) encoded by late gene 1. Based on the fact that L1 can self-assemble into virus like particle (VLP) with good immunogenicity, it has aroused wide concern in studying the pathogenesis of and vaccines against HPV. Nevertheless, there are a few limitations of present L1-based HPV vaccines. For instance, low expression of the protein and the com-plexity of purification result in the relatively low yield of vaccines. Type-specific antibody induced by L1 also results in the unsatisfactory cross-protection rate. Furthermore, there is no reported therapeutic effect against HPV-related diseases because of its undefined role in virus eliminating. This review focused on the struc-ture, immunogenicity and role in immune response of L1 and the development of and latest progress in HPV vaccines.